Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NY-BR-1 is a differentiation antigen of the mammary tissue, since it has been detected solely in the epithelial cells of mammary ducts and lobules, whereas NY-BR-1 expression has not been found in any other tissue. Thus, NY-BR-1 appears to be a breast-specific protein. In preliminary studies, NY-BR-1 mRNA was detected predominantly in breast cancers, and bioinformatic analysis annotated NY-BR-1 as a potential transcription factor. NY-BR-1 protein was shown to be expressed in normal breast epithelia and in the majority of primary breast cancers. NY-BR-1 may represent a potential target antigen for antibody-based therapy in breast cancer. Its frequent expression in breast cancer patients, its cell surface localization and accessibility to the monoclonal antibody mark NY-BR-1 as an attractive target.
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-LC218 | Anti-NY-BR-1 h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |||
| CAR-LC219 | Anti-NY-BR-1 h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | |||
| CAR-LC220 | Anti-NY-BR-1 h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | |||
| CAR-ZP2432 | Anti-NY-BR-1 (NYBR1#2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | NYBR1#2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP2433 | Anti-NY-BR-1 (NYBR1#2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | NYBR1#2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
